– BELGIUM, Mont-St-Guibert – Celyad Oncology (EBR: CYAD | Nasdaq: CYAD), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today announced the appointment of Dr. Georges Rawadi (Ph.D.) as its new CEO, effective as of March 23, 2023, replacing interim CEO Michel Lussier on April 17.
“It is with great enthusiasm that we announce that Georges has been appointed as our new CEO. His in-depth expertise in the CAR-T space and his significant BD and IP expertise are great assets that will help Celyad Oncology to excel in its next phase of growth. We congratulate Georges and wish him all the best in his new role,” said Board chair, Hilde Windels.
Interim CEO and Board member, Michel Lussier added, “We are convinced that Georges’s solid business development track record and immuno-oncology in-depth knowledge will make Georges a great leader for Celyad Oncology. We look forward to working with Georges in monetizing our IP and research assets, ensuring that Celyad Oncology can make an impact on a global scale.”
About Georges Rawadi
Georges Rawadi is a seasoned executive with over 20 years of experience in pharma/biotech, as a research director, business developer, CEO, and board member. He spent four years at Celyad Oncology (2014-2018) as VP of Business Development & Intellectual Property and has insightful knowledge of both the company and the CAR-T space. Georges Rawadi has a genuine passion for seeking and creating new business opportunities.
Georges Rawadi currently holds several Board positions and consultancy roles in the biotechnology industry. Recently, he has served as CEO and Board member of Ysopia Bioscience (France), VP of BD & IP of Celyad Oncology, and VP of Business Development of Nasdaq-listed company Cellectis.
Georges Rawadi holds a Master’s Degree in Biochemistry, a Master’s Degree in Microanalysis, a Ph.D. in Microbiology, and an Executive Master’s in Management and Strategy in the Health Industry.
Georges Rawadi said: “I am passionate about the space in which Celyad Oncology is operating and strongly believe in the value of its IP estate and efforts to overcome the current limitations of CAR-T approaches. As such, I am very pleased to be allowed to join Celyad Oncology. I look forward to working with the team and the board, whose passion and vision I share.”
About Celyad Oncology
Celyad Oncology is a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies. The Company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies. Celyad Oncology is based in Mont-Saint-Guibert, Belgium, and New York, NY.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.